INTRODUCTION
A frequency of 1% to 3% in patients exposed to unfractionated heparin (UFH) for more than four days may develop a heparin-platelet factor 4 antibodies mediated thrombocytopenia (1), known as heparin-induced thrombocytopenia (HIT) (2) . Usual HIT exhibits platelet count typically "20 !10 3 /μL, and spontaneous bleeding is unusual in contrast to idiopathic thrombocytopenic purpura with platelet count!10!10 3 /μL and clinical bleeding (3) . The major clinical problem associated with HIT is thrombosis, known as the heparin paradox. Delayedonset HIT was quite rare and seemed to account for about 3 to 5% of all HIT cases (4) . HIT with thrombotic complications after cardiac surgery under cardiopulmonary bypass (CPB) seemed to be associated with high mortality (5) . In this report, an extremely rare case with delayed-onset severe HIT with bleeding symptoms, without thrombosis, after total arch replacement is described with ultimate recovery.
CASE REPORT
Delayed-onset severe heparin-induced thrombocytopenia after total arch replacement under cardiopulmonary bypass 3 IU of UFH was given intravenously during CPB, which was initial exposure of heparin to him. When symptomatic atrial fibrillation (Af) was developed on postoperative day (POD) 7, a continuous intravenous administration of UFH (10!10 3 IU/day) was added and warfarin was started. Sinus rhythm resumed by cardioversion on POD 9. For preventing cardiogenic thromboembolism due to recurrent Af, UFH administration had been continued for the warfarin control achievement of PT-INR of 1.5-2.5. Finally, total UFH administration was kept for POD16.
Platelet count decreased to 56!10 3 /μL on POD 3 after cardiac surgery under CPB and increased gradually as usual to 420!10 3 /μL on POD 17. But it promptly decreased again to 3!10 3 /μL on POD 32, 16 days after re-exposure of UFH (Fig. 1) . Spontaneous oral submucosal hematoma and ecchymoma of bilateral lower legs requiring special attention were found at the same time. But thrombosis such as deep vein thrombosis and pulmonary embolism, venous limb gangrene, cerebral sinus thrombosis, stroke and acute myocardial infarction, was not found clinically and by contrast CT and echography.
As he had not taken medicines that caused thrombocytopenia and was not combined with severe infection and/or disseminated intravascular coagulation (DIC) associated diseaase, the presence of HIT syndrome was suspected. Warfarin was immediately discontinued, and argatroban, direct thrombin inhibitor, was immediately administrated at a dose of 0.5-2.5 μg/kg/min because of slight hepatic impairment. Target APTT of its treatment was 1.5-2.0 times normal APTT score. Serologic tests confirming antibodies against heparin-platelet factor 4 complexes, commonly known as HIT antibody, were performed. The optical density (OD) values of HIT antibody were 2.485, 2.314 and 2.116 on POD 32, 33 and 34, respectively ( Table 1) . The results greater than 2.00 OD value were assessed as a very strongly positive immunoassay result, which showed the probability of detecting platelet-activating antibodies was approximately 90%. In particular, clinically important heparin-platelet factor 4-IgG antibodies detected by peculiar enzyme immunoassay were 1.586, 1.640 and 1.479 OD values on POD 32, Platelet count exceeded above 100!10 3 /μL on 12 days of the therapy, and warfarin was reintroduced for a PT-INR of 1.5-2.5 and argatroban was discontinued. Hemorrhagic events had not been exacerbated, and no thrombosis had been appeared. Warfarin was reduced and discontinued with HIT antibody under the cut off level on POD 126.
DISCUSSION
Critical assessment of HIT suggests a frequency of 0.2 to 5.0 percentage in patients exposed to heparin for more than four days. Particularly, the incidence of HIT in patients who underwent cardiac surgery under CPB has been estimated to be 1.9% (6) . Without prompt diagnosis and proper treatment, patients with HIT complicated with venous and/or arterial thrombosis often result in dismal outcomes, with limb amputation in approximately 10%, and death in about 20%-30% (7).
Typical-onset HIT usually occurs at 5-14 days after initial exposure to a prophylactic or therapeutic dose of heparin (4). Furthermore, the peak onset is 5 to 8 days after starting heparin therapy (8) . Meanwhile, delayed-onset HIT begins with objectively proven venous and/or arterial thrombosis, with prompt thrombocytopenia developing after re-exposure of heparin following withdrawn of previous heparin. It seems to develop after re-exposure at a median time of 14 days (range : 9 to 40 days) (9) . In this case, the thrombocytopenia of the nadir platelet count of 3!10 3 /μL occurred promptly at 32 days from the initial exposure to heparin for CPB, and 16 days from the re-exposure to heparin for Af.
HIT is usually caused by IgG antibodies that are reactive against complexes of platelet factor 4 and heparin. The key factor of delayed-onset HIT seems to be antibodies that activate platelets in both a heparin-dependent and -independent manner, mimicking an autoimmune disease (10). Theodore et al. reported that patients with delayed-onset HIT have high-titer platelet-activating antibodies that exhibit increased heparin-dependent and independent platelet activation compared with typical-onset type (9) . It has been established that heparin-dependent antibodies recognize one or more sites on platelet factor 4 (11, 12) that are conformationally modified by pharmacologic heparin or endogenous glycosaminoglycans, such as endothelial-bound heparin sulfate (13, 14) . Therefore, delayed-onset HIT could be caused by high titers of heparin-dependent antibodies that recognize platelet factor 4 bound to the platelet surface in the absence of residual pharmacologic heparin, platelet factor 4 bound to endothelial glycosaminoglycans, or both. We believe it may be relevant to delayed-onset HIT etiology.
The first-step in establishing a diagnosis of HIT is suspecting the presence of this syndrome. However, one major difficulty in establishing the diagnosis of HIT was that medical and surgical patients (15) . The "4 T's" score of this patient was 2 points because of platelet nadir!10x10 3 /μL and no thrombosis, and was interpreted as low probability for HIT. Generally, patients with a low pretest probability of HIT do not have clinically significant HIT antibodies. Although it was difficult to determine whether or not HIT was present in this particular case, the presence of a secondary fall in the platelet count below 50 percent following arch replacement under CPB and absence of possible drug-induced thrombocytopenia appeared to be highly predictive of HIT. Moreover, severe thrombocytopenia unusual in HIT was associated with spontaneous bleeding, reported in past literature (16) . He showed a very strongly positive HIT antibody immunoassay result, which provided a definitive diagnosis of HIT.
Treatment of HIT consists of immediate cessation of all exposure to heparin and alternative anticoagulants that inhibit directly either coagulation factor Xa (fondaparinux) or thrombin (argatroban) in spite of different onset of HIT (9) . He underwent an alternative anticoagulant therapy with argatroban during the time remaining risk of thrombosis of other sequela. Argatroban was administrated from low dose because of his hepatic impairment, and was continued until the thrombocytopenia has resolved (17) .
CONCLUSION
In conclusion, if a patient manifests unexplained severe thrombocytopenia with spontaneous bleeding symptoms and heparin exposure within past 40 days, delayed-onset HIT should be kept in mind. Heparin should be discontinued immediately and alternative anticoagulant agents to heparin be started for preventing thrombosis of other sequalae, and the value of antibodies against the heparin-platelet factor 4 complex and the specific IgG antibody be measured simultaneously.
